Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ewa Lesko"'
Autor:
Mariusz Z Ratajczak, Barbara Zupanska, Jolanta Goźdizk, Ewa Lesko, Jacek Kijowski, Marcin Majka
Publikováno v:
Folia Histochemica et Cytobiologica, Vol 45, Iss 1, Pp 27-32 (2007)
The pathogenesis and tissue damage that accompanies destruction of platelets in immune thrombocytopenias (IT) is still not understood very well and in addition to platelets, other cells (e.g. endothelial cells, CD34+ hematopoietic stem/progenitors) m
Externí odkaz:
https://doaj.org/article/c60f433a672747959c72d17119453285
Autor:
Alfred B Jenson, Marcin Wysoczynski, Ewa Lesko, Justyna Drukala, Marcin Majka, Mariusz Z Ratajczak
Publikováno v:
Folia Histochemica et Cytobiologica, Vol 44, Iss 3, Pp 155-164 (2006)
Stromal Derived Factor-1 (SDF-1)-CXCR4 axis plays a pivotal role in biology and metastasis of several tumors. The aim of this study was to see if SDF-1 alone or in combination with Hepatocyte Growth Factor (HGF) affects biology of human cervical carc
Externí odkaz:
https://doaj.org/article/aa4f476e05a84d8a821d8b31852b6231
Autor:
Anna Mordel, Marcin Majka, Ewa Lesko, Wojciech Czogała, Danuta Kowalczyk, Marek Zembala, Oktawiusz Wiecha, Szymon Skoczeń, Aleksandra Krasowska-Kwiecień, Jolanta Gozdzik
Publikováno v:
Pediatric Transplantation. 13:760-765
OS is a variant of SCID characterized by generalized erythroderma, alopecia, eosinophilia, and elevated IgE levels. It is fatal unless treated with allogeneic HSCT, which is the only curative approach. However, treatment related complications and gra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a86df96b2b629f241fb3ee1ff8f11ae9
https://doi.org/10.1111/j.1399-3046.2008.01020.x
https://doi.org/10.1111/j.1399-3046.2008.01020.x
Publikováno v:
Open Life Sciences, Vol 3, Iss 4, Pp 371-379 (2008)
Silencing of a target-genes by small interfering RNA (siRNA) has emerged as a powerful new tool not only for basic research but also with potential therapeutic benefits. This paper demonstrates that optimal delivery strategy is crucial for effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c25a59668b6d0393a311490e6dd724d
https://doi.org/10.2478/s11535-008-0042-5
https://doi.org/10.2478/s11535-008-0042-5
Publikováno v:
Anti-cancer drugs. 18(10)
In this study, geldanamycin (GA) was found to have an antiproliferative effect on both embryonal and alveolar rhabdomyosarcoma (RMS) cell lines. The maximum level of inhibition reached 80% for both embryonal and alveolar RMS. After GA treatment, cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94c36e3a0d582141cc617f9a80be74c9
https://pubmed.ncbi.nlm.nih.gov/17893518
https://pubmed.ncbi.nlm.nih.gov/17893518
Autor:
Ewa Lesko, Marcin Majka
Publikováno v:
Frontiers in Bioscience. 13:1271
Hepatocyte growth factor (HGF) and its receptor MET play an important role in cancer growth and metastasis. Activation of MET elicit multiple cellular responses regulating cell survival, morphogenesis, adhesion, migration, breakdown of extracellular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d84eb771b1d91d5eb21ed1f9e4273412
https://doi.org/10.2741/2760
https://doi.org/10.2741/2760
Publikováno v:
Blood. 110:1926-1926
Rhabdomyosarcoma (RMS) is a pediatric soft tissue sarcoma belonging to family of small blue cell tumors and it represents the largest subset of soft tissue sarcomas in this age group. RMS can be divided into two major subtypes based on chromosomal an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f6605acd747f3a03e6ad5af5f43fddc
https://doi.org/10.1182/blood.v110.11.1926.1926
https://doi.org/10.1182/blood.v110.11.1926.1926
Publikováno v:
Blood. 108:2566-2566
The potential for multilineage differentiation together with the ability to expand in cultures are the reasons why Mesenchymal Stem Cells (MSC) are considered to be the population of stem cells for potential treatment for variety of disorders (e. g.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::604a666e58f7aea9e5ac7a937a580f54
https://doi.org/10.1182/blood.v108.11.2566.2566
https://doi.org/10.1182/blood.v108.11.2566.2566
Autor:
Aleksander B. Skotnicki, Wojciech Czogała, Artur Jurczyszyn, Marcin Majka, Jolanta Gozdzik, Ewa Lesko, Anna Zebzda
Publikováno v:
Blood. 108:5027-5027
Multiple Myeloma (MM) is the second most commonly diagnosed hematologic malignancy and still an incurable disease with dismal prognosis and average survival of 3 – 4 years. None of conventional therapies gives total cure or long survival, so it is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b32a6e505de240b581308987986446c
https://doi.org/10.1182/blood.v108.11.5027.5027
https://doi.org/10.1182/blood.v108.11.5027.5027
Autor:
Teresa Wolska-Smoleń, Jolanta Gozdzik, Zbigniew Rudzki, Aleksander B. Skotnicki, Mariusz Z. Ratajczak, Artur Jurczyszyn, Marcin Majka, Anna Zebzda, Wojciech Czogała, Ewa Lesko
Publikováno v:
ResearcherID
Despite progress in the treatment of Multiple Myeloma (MM), it is still an incurable disease with average survival of 3–4 years. Because MM is often resistant to conventional therapies, new treatment strategies are necessary. The presence of elevat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f631246cfeeb4193c49b3117380a527
https://doi.org/10.1182/blood.v106.11.3395.3395
https://doi.org/10.1182/blood.v106.11.3395.3395